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Abstract
Background: Amyloid pathology is the pathological hallmark in Alzheimer’s disease (AD) and can precede clinical
dementia by decades. So far it remains unclear how amyloid pathology leads to cognitive impairment and dementia.
To design AD prevention trials it is key to include cognitively normal subjects at high risk for amyloid pathology and to
find predictors of cognitive decline in these subjects. These goals can be accomplished by targeting twins, with
additional benefits to identify genetic and environmental pathways for amyloid pathology, other AD biomarkers,
and cognitive decline.
Methods: From December 2014 to October 2017 we enrolled cognitively normal participants aged 60 years and
older from the ongoing Manchester and Newcastle Age and Cognitive Performance Research Cohort and the
Netherlands Twins Register. In Manchester we included single individuals, and in Amsterdam monozygotic twin
pairs. At baseline, participants completed neuropsychological tests and questionnaires, and underwent physical
examination, blood sampling, ultrasound of the carotid arteries, structural and resting state functional brain magnetic
resonance imaging, and dynamic amyloid positron emission tomography (PET) scanning with [18F]flutemetamol. In
addition, the twin cohort underwent lumbar puncture for cerebrospinal fluid collection, buccal cell collection,
magnetoencephalography, optical coherence tomography, and retinal imaging.
Results: We included 285 participants, who were on average 74.8 ± 9.7 years old, 64% female. Fifty-eight participants
(22%) had an abnormal amyloid PET scan.
Conclusions: A rich baseline dataset of cognitively normal elderly individuals has been established to estimate risk
factors and biomarkers for amyloid pathology and future cognitive decline.
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Background
Alzheimer’s disease (AD) is the most common cause of
dementia and is characterized by amyloid plaques and
neurofibrillary tangles with subsequently progressive
neuronal loss and eventually death [1]. Aggregation of
amyloid is supposed to be the first event in AD and
starts years before cognitive impairment occurs [2–4].
Postmortem pathological and biomarker studies have
demonstrated that 20–40% of cognitively normal elderly
individuals possess abnormal amyloid levels in their
brain [4–9]. These subjects are considered to be in the
preclinical stage of AD [10, 11]. This presymptomatic
window provides a unique opportunity for secondary
prevention studies, as subjects have limited brain dam-
age and no symptoms yet. Understanding the patho-
physiological mechanisms underlying amyloid pathology
in this preclinical stage of AD might also be critical to
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identify possible drug targets for the development of ef-
fective treatments.
There are, however, several research challenges for the
development of prevention strategies in the preclinical
AD stage. First, amyloid markers are needed for the
diagnosis of preclinical AD. There is an urgent need for
readily applicable screening markers, such as blood or
imaging markers, to identify cognitively normal subjects
at increased risk for amyloid pathology so that more ex-
pensive or invasive tests such as positron emission tom-
ography (PET) scan or cerebrospinal fluid (CSF) via
lumbar puncture can be performed in more selected
populations. A number of markers have already been
identified for this purpose but these need to be validated
in preclinical/prodromal stages of the disease [12–15].
Second, there is still an incomplete understanding of
what drives the development of amyloid pathology in
cognitively normal subjects. Previous studies have identi-
fied a limited number of risk factors for amyloid path-
ology, such as Apolipoprotein E (APOE) genotype, age,
and level of education [4, 16–18]. These established risk
factors, however, can only explain part of the risk for
amyloid pathology. Third, amyloid pathology has been
associated with an increased risk for cognitive decline,
but the rate of decline varies greatly [19]. A few possible
prognostic factors in preclinical AD have been identified
but they await replication [20, 21]. Fourth, current nor-
mative data for biomarkers and cognitive markers may
be suboptimal as many cognitively normal subjects
already have amyloid pathology. Finally, CSF and PET
biomarkers for amyloid pathology do not match in about
15% of cases [22–24], in particular in cognitively normal
subjects. It has been suggested that amyloid changes can
be detected earlier in CSF than by PET but this requires
further investigation [25].
In this paper, we describe the study design of the mul-
tisite PreclinAD study, which aims to address these
clinical research challenges. Within this study, cogni-
tively normal elderly individuals are recruited from the
Manchester and Newcastle Age and Cognitive Perform-
ance Research Cohort (ACPRC) in Manchester [26] and
the Netherlands Twin Register (NTR) in Amsterdam
[27]. From the NTR we recruited monozygotic (MZ)
twins. When a relation is observed between two
markers, studying MZ twins enables exploring the na-
ture of the observed relation: the MZ twin differences
approach gives the possibility to study the relation ex-
cluding confounding by genetic factors (the twins are
genetically identical); and the cross-twin cross-trait de-
sign, studying whether marker 1 in one twin can predict
marker 2 in their co-twin, gives the opportunity to study
the contribution of shared familial factors (genes and
common environment) to the relation. Previous studies
using AD-type dementia as an outcome estimated the
amount of variance explained by genetic factors to be
around 80% [28], suggesting a major genetic role in the
development of AD. However, there is a lack of studies
estimating the contribution of genetic and environmen-
tal influences on AD biomarkers in nondemented indi-
viduals and the role of environmental risk and protective
factors for AD remains unclear [18].
The PreclinAD study aimed to: validate existing and
discover new markers for amyloid pathology in cogni-
tively normal elderly individuals; identify risk factors for
amyloid pathology; identify prognostic markers for cog-
nitive decline in cognitively normal subjects with amyl-
oid pathology (Fig. 1); and determine the contribution of
genetic and environmental influences on these markers.
Methods
Project
The European Medical Information Framework for AD
The study is part of the Innovative Medicine Initiative
European Medical Information Framework for AD
Fig. 1 Hypothetical model of amyloid pathology. Hypothetical model for evaluating risk factors for amyloid pathology, for cognitive decline in
subjects with amyloid pathology and other markers that might be involved in early AD pathology. (I) Markers for amyloid pathology in cognitively
healthy elderly individuals; (II) risk factors for amyloid pathology; (III) prognostic markers for cognitive decline in cognitively normal subjects with
amyloid pathology
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(EMIF-AD) project, which aims to facilitate the develop-
ment of treatment for AD in nondemented subjects
(http://www.emif.eu/) by discovering and validating diag-
nostic markers, prognostic markers, and risk factors for
AD in nondemented subjects using existing data resources
where possible.
Sample selection
We included 81 cognitively normal participants from the
ACPRC. The ACPRC originally comprised over 6000
adults from the North of England, UK, who underwent
detailed batteries of cognitive function biannually until
2003 [26]. In 1999 and 2000, active members of this co-
hort were invited and consented to provide a deoxyribo-
nucleic acid (DNA) sample to the Dyne-Steel DNA
Archive for study of Cognitive Genetics in later life. In
2003, a subsample of 500 Manchester volunteers under-
went detailed physical examination and provided sam-
ples of saliva, serum, and plasma. Over time, the cohort
has reduced in size through attrition, largely by mortal-
ity, to a number of approximately 660 volunteers. Since
2003, study participants have been assessed biannually
with a smaller battery of tests and rating scales in order to
diagnose pathological cognitive impairment and emotional
problems. The current study coincides with the fourth
wave of follow-up investigations. In Amsterdam, monozy-
gotic twins were recruited from the NTR [29]. The NTR
started recruiting adolescent and adult twins and their rel-
atives in 1987 and had included over 200,000 participants
by 2012 [27]. Twins who gave consent for the NTR also
allow researchers to approach them for participation in
scientific studies. From 1991 onward, participants com-
pleted extensive questionnaires every 2 or 3 years and
DNA was collected in the NTR-Biobank project [30].
Smaller subgroups of participants underwent biomarker
collection such as laboratory tests, electroencephalogram,
or magnetic resonance imaging (MRI) [31–33]. The
current study is a new NTR sub study.
Ethical considerations
The National Research Ethics Service Committee
North West—Greater Manchester South performed
ethical approval of the study in Manchester. The
Medical Ethics Review Committee of the VU Univer-
sity Medical Center performed approval of the study
in Amsterdam. Research was performed according to the
principles of the Declaration of Helsinki and in accord-
ance with the Medical Research Involving Human Sub-
jects Act and codes on ‘good use’ of clinical data and
biological samples as developed by the Dutch Federation
of Medical Scientific Societies. All participants gave writ-
ten informed consent.
Inclusion criteria
Inclusion criteria for the PreclinAD cohort were age
60 years and older, a delayed recall score above − 1.5 SD
of demographically adjusted normative data on the
Consortium to Establish a Registry for Alzheimer’s Disease
10-word list [34, 35], a Telephone Interview for Cognitive
Status-modified score of 23 or higher [36], a 15-item
Geriatric Depression Scale score < 11 [37], and a Clinical
Dementia Rating score of 0 [38] (Additional file 1: Table S1).
Exclusion criteria
To avoid possible interference with normal cognition, sub-
jects with the following medical conditions, at present or
in the past, were excluded: diagnosis of mild cognitive im-
pairment (MCI), probable AD or other neurodegenerative
disorders such as Huntington disease, cortical basal de-
generation, multiple system atrophy, Creutzfeldt-Jakob
disease, primary progressive aphasia or Parkinson’s dis-
ease, stroke resulting in physical impairment, epilepsy
with current use of antiepileptic drugs, brain infection
(e.g., herpes simplex encephalitis), brain tumor, severe
head trauma with loss of consciousness longer than 5 min,
cancer with terminal life expectancy, untreated vitamin
B12 deficiency, diabetes mellitus, thyroid disease, schizo-
phrenia, bipolar disorders, or recurrent psychotic disor-
ders. Furthermore, a history of recreational drug use,
alcohol consumption > 35 units per week (1 unit = 10 ml
or 8 g of pure alcohol), use of high-dose benzodiazepine,
lithium carbonate, antipsychotics (including atypical
agents), high-dose antidepressants, or Parkinson’s disease
medication were exclusion criteria. Finally, subjects who
were not able to attend the hospital due to physical mor-
bidity or illness or who had a contraindication for MRI
(e.g., metal implants, pacemaker, etc.) were excluded
(Additional file 1: Table S1).
Data collection
Neuropsychological testing battery and questionnaires
During a 4-h screening research facility visit (Manchester)
or home visit (Amsterdam), participants underwent exten-
sive neuropsychological testing and questionnaires. A
complete overview of the neuropsychological testing bat-
tery and questionnaires is presented in Additional file 2:
Table S2 and Additional file 3: Table S3, respectively. In
short, we assessed memory function with the Rey auditory
verbal learning task [39], visual association task [40],
face–name associative memory examination [41], Rey
complex figure recall [42], CANTAB paired associate
learning [43], and digit span [44]. We also tested verbal
fluency, naming [45], visuo-constructional skills, and
executive functions [42, 46, 47] (see Additional file 2:
Table S2). Using questionnaires we assessed social and
physical activities [48–50], sleep quality [51, 52], activities
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of daily living [53, 54], memory complaints [55], and psy-
chiatric symptoms [56] (see Additional file 3: Table S3).
Physical examination
Data on waist circumference, hip circumference, body
mass index, resting blood pressure, heart rate, and grip
strength of the dominant hand were collected for all par-
ticipants (Table 1). In Manchester, an ankle/brachial
pressure index and a 4-min walking test were also per-
formed. In Amsterdam, a trained physician performed
exploratory neurological examination. In addition, bio-
electrical impedance analysis, repeated resting blood
pressure measurement, and lead 1 of an electrocardio-
gram (measured by holding a Diagnostick [57] for 1
min) were performed and a color photograph of the face
of each participant was taken. See Table 1 and Add-
itional file 4: Table S4 for all biomarker data availability.
Blood collection
For all participants, 50 ml of blood was collected in the
morning, after 2 h of fasting, including EDTA blood for
DNA isolation, plasma, and buffy coat, clotted blood for
serum, and Paxgene tubes for RNA isolation. Immediate
plasma analysis was performed for complete blood
count, hemoglobin A1C, 2-h fasting glucose, liver en-
zymes, lipid spectrum, C-reactive protein, erythrocyte
sedimentation rate, thyroid stimulating hormone, and
vitamin B12. EDTA tubes with anticoagulated whole
blood were centrifuged at 1300–2000 × g for 10 min,
and plasma and remaining buffy coat were, like whole
blood for collecting serum, aliquoted according to the
standardized operating procedures of the BIOMAR-
KAPD project [58] in aliquots of 0.25–0.5 ml and stored
locally until analysis. All samples were stored at − 80 °C
within 2 h. Two 2.5-ml Paxgene tubes were stored at
room temperature for a minimum of 2 h and a max-
imum of 72 h, before they were frozen at − 20 °C until
RNA isolation. The EDTA whole blood tube for DNA
analysis was stored at − 20 °C until isolation.
DNA and RNA collection
Extraction of DNA and RNA from peripheral blood sam-
ples was performed at both sites. In addition, at the
Amsterdam site, buccal cells were collected for zygosity,
genome-wide association studies, and epigenetics [59].
Amsterdam participants were genotyped on the Affyme-
trix Axiom array and the Affymetrix 6 array [60]; these
were first cross-chip imputed following the protocols de-
scribed by Fedko et al. [61] and then imputed into HRC
with the Michigan Imputation server [62]. The APOE ge-
notypes were assessed using isoforms in Manchester as
described by Ghebranious et al. [63]. In Amsterdam, the
APOE genotype was assessed using imputed dosages of
the SNPs rs429358 (APOE ɛ4, imputation quality = 0.956)
and rs7412 (APOE ɛ2, imputation quality = 0.729) [64].
Ultrasound carotid artery
In Manchester, a duplex ultrasound scan of the left and
right carotid arteries was performed to collect data on
velocity, vessel thickness, stenosis, and plaques rated ac-
cording to the North American Symptomatic Carotid
Endarterectomy Trial guidelines [65]. In Amsterdam, a
duplex ultrasound scan of the right carotid artery was
performed to assess intima media thickness and disten-
sion using ArtLab software [66–68].
Magnetic resonance imaging
Acquisition protocol In Manchester, brain scans were
performed at the Wellcome Trust Manchester Clinical
Research Facility (Central Manchester University
Hospital NHS Foundation Trust). All MRI investigations
were performed on a 3 T Philips Achieva scanner using
a 32-channel head coil. Participants underwent an MRI
protocol that included 3D-T1, 3D fluid-attenuated inver-
sion recovery (FLAIR), pseudocontinuous arterial spin
labeling (ASL), and quantitative magnetization transfer
scans. In Amsterdam, brain scans were also obtained
using a 3 T Philips Achieva scanner equipped with an
eight-channel head coil. The MRI protocol included
structural 3D-T1, FLAIR, pseudocontinuous ASL, sus-
ceptibility weighted imaging (SWI), diffusion tensor im-
aging (DTI), and 6 min of resting state functional MRI
(rs-fMRI). The MRI settings are presented in Add-
itional file 5: Table S5.
Visual assessment All MRI scans were reviewed for in-
cidental findings by an experienced neuroradiologist,
and visually rated by a single experienced rater (MtK)
who was blinded to demographic information and twin
pairing at the moment of rating. White matter hyperin-
tensities were visually assessed on the FLAIR images
using the 4-point Fazekas scale (none, punctuate, early
confluent, confluent) [69]. Lacunes were defined as deep
lesions from 3 to 15 mm with CSF-like signal on
T1-weighted and FLAIR images. Microbleeds were
assessed on SWI scans and defined as rounded hypoin-
tense homogeneous foci of up to 10 mm in the brain
parenchyma. Medial temporal lobe atrophy was assessed
on coronal reconstructions of the T1-weighted images
using a 5-point visual rating scale [70]. Global cortical
atrophy was rated on transversal FLAIR images using a
4-point scale [71]. Posterior cortical atrophy was
assessed using a 4-point visual rating scale [72].
Amyloid positron emission tomography
[18F]flutemetamol In both centers, [18F]flutemetamol
was used as a fibrillar amyloid radiotracer.
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Table 1 Sample characteristics
Demographic n Combined sample n Amsterdam site n Manchester site
(n = 285) (n = 204) (n = 81)
Age (years) 285 75.0 (9.7)
(range 60–95)
204 70.8 (7.8)
(range 60–94)
81 85.7 (4.3)***
(range 79–95)
Gender (% female) 285 182 (64%) 204 119 (58%) 81 63 (78%)**
Education (years) 278 14.8 (4.2) 204 14.9 (4.5) 74 14.2 (3.0)
NART 285 41.9 (6.0) 204 41.2 (6.4) 81 43.7 (4.3)***
MMSE 281 28.9 (1.2) 204 28.9 (1.2) 77 28.7 (1.3)
TICS-m 282 28.3 (3.2) 204 28.3 (3.0) 78 28.5 (3.7)
CERAD 10-word recall 285 22.8 (3.3) 204 22.0 (3.0) 81 24.8 (3.3)***
GDS 282 1.0 (1.5) 204 0.7 (1.2) 78 1.9 (1.7)***
CDR total 284 0 (0.1) 204 0 80 0.03 (0.1)*
CDR sum of boxes 284 0.03 (0.1) 204 0 80 0.1 (0.3)**
APOE e4 carrier 282 85 (30%) 202 66 (33%) 80 19 (24%)
APOE4 genotype 282 202 80
e2e2 2 (1%) 2 (1%) –
e2e3 24 (9%) 12 (6%) 12 (15%)
e2e4 9 (3%) 6 (3%) 3 (4%)
e3e3 171 (61%) 122 (60%) 49 (61%)
e3e4 69 (25%) 54 (27%) 15 (19%)
e4e4 7 (3) 6 (3%) 1 (1%)
Family history dementia 273 106 (39%) 203 92 (45%) 70 14 (20%)***
Diabetes type II – – 204 13 (6%) – –
Current smoker 281 23 (8%) 203 21 (10%) 78 2 (3%)
Alcohol use present 282 224 (79%) 204 158 (77%) 78 66 (85%)
Blood pressure (mmHg) 281 152 (21)/80 (12) 202 155 (21)/83 (11) 79 143 (19)/70 (10)***
Pulse rate (beats/min) 279 66 (11) 202 65 (11) 77 69 (10)**
Height (m) 283 1.66 (0.10) 204 1.69 (0.09) 79 1.60 (0.08)***
Weight (kg) 283 73.1 (14.0) 204 75.7 (13.6) 79 66.6 (13.0)***
Body mass index 283 26.3 (4.0) 204 26.4 (3.8) 79 26.1 (4.3)
Waist circumference (cm) 282 93.4 (13.6) 203 94.7 (12.0) 79 89.9 (16.6)**
Hip circumference (cm) 234 101.9 (11.4) 155 102.6 (9.8) 79 100.5 (14.0)
Grip strength (kg) 283 28.5 (11.3) 204 30.9 (10.9) 79 22.2 (9.8)***
CSF Aβ1–42 (pg/ml) – – 126 889 (314) – –
CSF Aβ1–40 (pg/ml) – – 126 9592 (2844) – –
Ratio CSF Aβ1–42/1–40 – – 126 0.10 (0.03) – –
CSF total-tau (pg/ml) – – 126 412 (143) – –
CSF p-tau 181 (pg/ml) – – 126 76 (44) – –
Visual read PET abnormal 272 58 (22%) 196 32 (16%) 76 26 (34%)**
Fazekas score 279 1.3 (0.9) 199 1.2 (0.8) 80 1.7 (0.8)***
Medial temporal lobe atrophy score (average left and right) 277 0.7 (0.7) 197 0.6 (0.7) 80 0.9 (0.6)*
Parietal atrophy (average left and right) 279 1.1 (0.7) 199 1.1. (0.7) 80 1.2 (0.6)*
Data presented as mean (standard deviation) or n (%)
NART National Adult Reading Test, MMSE Mini-Mental State Examination, TICS-m Modified Telephone Interview for Cognitive Status, CERAD Consortium to Establish
A Registry for Alzheimer’s Disease, GDS Geriatric Depression Scale, CDR Clinical Dementia Rating, APOE Apolipoprotein E, CSF cerebrospinal fluid, Aβ amyloid beta,
p-tau phosphorylated tau, PET positron emission tomography
***p < 0.001, **p < 0.01, *p < 0.05, group difference assessed with t test or chi-square test
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[18F]flutemetamol is an 11C-Pittsburgh compound B
(PiB) derivative radiolabeled with 18F and has structural
similarity to PiB, which is a frequently used compound
for in-vivo detection of amyloid plaques [73]. In Man-
chester, the tracer [18F]flutemetamol was produced at
the Wolfson Molecular Imaging Centre (WMIC) Good
Manufacturing Practice radiochemistry facility using
General Electric Healthcare’s (GEHC) FASTlab and cas-
settes. For Amsterdam, the same tracer was produced at
the Cyclotron Research Center of the University of Liège
(Liège, Belgium). GEHC was responsible for production
and transportation of [18F]flutemetamol. Prior [18F]flute-
metamol studies showed good brain uptake and radi-
ation dosimetry similar to other radiopharmaceuticals in
clinical use, test–retest variability for image quantitation
differentiation between healthy participants and patients
with AD, and the ability to detect brain Aβ [73].
Acquisition protocol At both sites, all participants were
scanned dynamically from 0 to 30 min and then again
from 90 to 110 min after intravenous injection of
185 MBq (± 10%) [18F]flutemetamol. The initial scan
(0–30 min) was shortened or omitted if it was not ac-
cepted or tolerated by the participant. The second time
window (90–110 min) is the recommended interval for
assessment of amyloid biomarker abnormality. In
Manchester, all PET scans were performed on a
high-resolution research tomograph brain scanner (HRRT;
Siemens/CTI, Knoxville, TN, USA) at the WMIC of the
University of Manchester. Two 7-min transmission scans
using a 137Cs point source were acquired for subsequent
attenuation and scatter correction; one prior to the first
emission scan, and another following the second emission
scan [74, 75]. In Amsterdam, all PET scans were
performed using a Philips Ingenuity Time-of-Flight PET–
MRI scanner at the Department of Radiology & Nuclear
Medicine of the VU University Medical Center. Immedi-
ately prior to each part of the PET scan, a dedicated MR
sequence (atMR) was performed for attenuation correc-
tion of the PET image [76]. For both sites, the first dy-
namic emission scan was reconstructed into 18 frames
with progressive increase in frame length (6 × 5 s, 3 × 10 s,
4 × 60 s, 2 × 150 s, 2 × 300 s, 1 × 600 s). The second part
of the scan consisted of 4 × 5-min frames. During scan-
ning, the head was immobilized to reduce movement arti-
facts using laser beams.
Visual assessment All [18F]flutemetamol amyloid PET
scans were checked for movement and the frames were
summed to obtain a static image (90–110 min). PET im-
ages were visually read as abnormal or normal by an ex-
perienced reader (SFC in Manchester and BNMvB in
Amsterdam), blinded to clinical and demographic data,
according to GEHC guidelines described in the summary
of product characteristics [77].
CSF collection (Amsterdam site only)
Up to 20 ml of CSF was obtained by lumbar puncture in
Sarstedt polypropylene syringes using a Spinocan
25-gauge needle in one of the intervertebral spaces be-
tween L3 and S1. One milliliter was immediately proc-
essed for leukocyte count, erythrocyte count, glucose, and
total protein. The remaining CSF was mixed and centri-
fuged at 1300–2000 × g for 10 min at 4 °C. Supernatants
were stored in aliquots of 0.25–0.5 ml and frozen within 2
h at − 80 °C and stored for future biomarker discovery
studies [78]. Levels of amyloid β1–40 and β1–42 were an-
alyzed using kits from ADx Neurosciences/Euroimmun
according to the manufacturer’s instructions. All samples
were measured in kits from the same lot.
Magnetoencephalography (Amsterdam site only)
Magnetoencephalography (MEG) measurements were re-
corded using a 306-channel, whole-head MEG system
(ElektaNeuromag Oy, Helsinki, Finland) in a magnetically
shielded room (Vacuumschmelze GmbH, Hanau,
Germany). Participants were instructed to lie on a bed with
their eyes closed but to stay awake and reduce eye
movements in order to minimize artifacts. Participants
were scanned for 5 min with eyes closed, 2 min with eyes
open, and another 5 min with eyes closed. On MEG we
used source-reconstructed time series (https://doi.org/
10.1016/j.neuroimage.2011.11.005) to extract both fre-
quency spectrum properties (relative band power and peak
frequency) and functional connectivity between regions, as
well as network topology using modern network theory
(synchronization likelihood, modularity, path length, phase
lag index) [79, 80]. These analysis techniques were applied
using BrainWave software (http://home.kpn.nl/stam7883/
brainwave.html) [81] and inhouse MATLAB scripts
(MATLAB Release 2012a; The MathWorks, Inc., Natick,
MA, USA).
Ophthalmological markers (Amsterdam site only)
Exploratory eye examination An exploratory eye
examination including measurement of best corrected
visual acuity, refractive error, and intra-ocular pressure
(noncontact tonometry) was performed. In a subsample
(n = 50), slit lamp examination by a trained physician
was performed as well.
Ocular coherence tomography Ocular coherence tom-
ography (OCT) was performed using the Heidelberg
Spectralis. With OCT we measured retinal nerve fiber
layer tissue, total macular thickness, and the thickness of
macular individual retinal layers using the built-in seg-
mentation software from the Spectralis [82], which
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might correlate with cerebral amyloid pathology [83].
With the same device, fundus autofluorescence was per-
formed to try to detect degenerative retinal abnormal-
ities possibly related to amyloid pathology [83, 84].
Retinal imaging Using a nonmydriatic camera (Topcon),
two digital images (mostly 50°, and some 30°) per eye were
taken of the retina—one centered to the macula, and the
other to the optic nerve head—after pupil dilation with
tropicamide. On the digitalized fundoscopy image we
measured retinal vascular parameters using the Singapore
I vessel Assessment software [85].
Data management
Data were stored in the online database CASTOR
(https://castoredc.com/) with restricted access. Each site
provided clinical information and sample information to
the database according to a predefined case report form.
Blood and CSF samples, PET and MRI scans, and MEG
data are stored locally until centralized analysis.
Follow-up visit
A follow-up visit including neuropsychological testing,
questionnaires at both sites, and physical examination,
blood sampling, buccal cell collection, and lumbar
puncture in a subset will be performed after 21 months
± 3 months.
Follow-up started in February 2017 and is still on-
going. So far 241 individuals have been invited, and of
those 221 (92%) participated in the follow-up.
For the twin pairs, an additional follow-up visit after
4 years is planned, starting in January 2019. This follow-up
includes amyloid-PET, tau-PET, MRI, lumbar puncture,
neuropsychological testing, questionnaires, physical exam-
ination, blood sampling, and buccal cell collection.
Statistical approaches
Group analysis
The main outcome measure will be the presence of
amyloid pathology as a dichotomous and continuous
outcome measure. We aim to identify for each diagnos-
tic modality the best set of predictors for amyloid path-
ology using step forward selection. The best predictors
for each modality will be combined in a single risk
score, based on the β value of these predictors in the
regression model. Analysis will be performed using
multivariate multilevel generalized estimating equation
analysis with correction for age, gender, education, and
twin status (Amsterdam only) [86]. In addition, as there
are differences between the cohorts, we will correct for
cohort in the analysis and test interactions of predictor
variables with cohort to check whether pooling the data
may introduce a bias.
Results
Inclusion
Manchester
From the ACPRC, 321 subjects in total were invited by
letter to participate in the PreclinAD study. From this
selection, 81 subjects were included for participation
(see Fig. 2a).
Amsterdam
In total 517 twins from the NTR were invited by letter. Of
these, 100 complete pairs (99 MZ, one dizygotic, as con-
firmed with DNA analysis) and four singletons, of which
the co-twin did not meet the inclusion criteria due to cog-
nitive impairment of other neurological conditions, were
included (see Fig. 2b). This also included one twin who ap-
peared to be demented at baseline hospital visit, even
though this subject passed the inclusion criteria at first, and
one subject from a monozygotic triplet, which we included
due to the unique opportunity to analyze a genetically iden-
tical triplet, but this subject did not meet the inclusion cri-
teria due to MCI. All participants, except for one twin pair,
have European descent. When analyzing genetic data this
twin pair will be excluded from the analysis.
Demographics and biomarkers
Participants were on average 74.8 years old, 64% female, and
30% APOE ε4 carriers; for further baseline characteristics see
Table 1. Participants tested in Manchester were older
compared to Amsterdam participants (85.7 vs
70.8 years, p < 0.001) and more often female (78 vs 58%,
p < 0.01). Manchester participants also had a higher
intelligence score according to the Adult Reading Task
(43.7 vs 41.2, p < 0.001), less often a family member
with dementia (20 vs 45%, p < 0.001), lower blood pres-
sure, (143/70 vs 155/83 mmHg, p < 0.001), and higher
white matter lesion load according to the Fazekas score
(1.7 vs 1.2, p < 0.001) (Table 1).
Amyloid data were available for 275 participants
(Manchester n = 76, Amsterdam n = 199). In Amsterdam,
123 participants had both CSF and PET available, 73 PET
only, and three CSF only. For 10 participants we were un-
able to assess their amyloid status: six participants were
not able to attend the hospital after inclusion, one partici-
pant did not undergo PET due to meningiomas on MRI,
two participants suffered from claustrophobia during the
hospital visit, and one participant had a panic attack be-
fore injection of the PET tracer. Dynamic PET scans were
present in 261 participants: four participants failed their
dynamic scan due to logistic problems, and in seven par-
ticipants quality control of the images failed.
Amyloid pathology
Of the 272 participants with a static PET amyloid meas-
ure available, 58 (21%) had an abnormal PET scan as
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Fig. 2 Inclusion flow chart for participants from a Manchester invited subjects selected from a sample of 660 subjects who were part of
Manchester and Newcastle Age and Cognitive Performance Research Cohort (ACPRC, Manchester) at time of recruitment and b from Amsterdam
invited twins selected from a sample of 678 monozygotic twins who were actively registered in Netherlands Twin Register (Amsterdam) at time
of recruitment
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visually read on a summed static PET image. An abnor-
mal PET was less common in Amsterdam (16%) than
in Manchester (34%) (p < 0.001). The prevalence of ab-
normal amyloid PET scans was higher in older age
groups (Fig. 3).
Discussion
The PreclinAD study is a prospective cohort study of
285 cognitively normal elderly individuals with extensive
phenotyping for amyloid pathology, neurodegeneration
markers, cognition, and lifestyle factors.
We noted some differences in baseline characteristics
between the Manchester and Amsterdam sites. This
could mainly be explained by the higher age in the
Manchester substudy. The prevalence of amyloid path-
ology increased with age, although the prevalence was
somewhat lower than would be expected based on a
large subject-level meta-analysis, in particular in the age
range below 80 years [4]. This might be explained by the
relatively healthy sample of participants, due to the strict
inclusion and exclusion criteria.
The Amsterdam sub study is the first to assess a wide
range of AD markers in a large sample of cognitively
normal monozygotic twin pairs above age 60 years. The
uniqueness of studying a cohort of twin pairs sharing
100% of their genetic material enables us to further ex-
plore the nature of the relation between AD markers. If
MZ twin pairs are highly similar for AD markers, this
suggests involvement of shared genetic and/or shared
environmental factors, whereas within-pair differences
indicate the involvement of unique environmental fac-
tors [87]. The strength of the MZ twin within-pair differ-
ence model further enables us to identify environmental
risk factors (e.g., smoking, alcohol use, diet, sleep, phys-
ical activity, cognitive activity, and education) that, either
directly or indirectly through epigenetic mechanisms,
explain observed differences in AD markers within pairs.
This may provide clues for novel preventive and thera-
peutic strategies. However, this model also has the disad-
vantage that, because MZ twins are genetically identical,
we have to correct for twin dependency in all analysis,
which may reduce statistical power [86]. Further, we did
not include dizygotic twins in the current study, because
this optimizes power for twin difference analysis, thereby
strengthening the search for environmental risk factors
influencing AD development. However, this has the dis-
advantage that the relative contribution of shared gen-
etic and shared environmental factors to within-pair
correlations cannot be estimated. Still, previous studies
in elderly twins suggested that the contribution of
shared environment at older age is highly limited, pos-
sibly because subjects have already been living apart for
a longer period of time [88, 89].
A strength of our study, compared to other studies on
preclinical AD, is that participants have been recruited
from cohorts that have been ongoing for up to 20 years,
which provides the possibility to test biomarkers, cogni-
tion, and lifestyle collected in the past as predictors for
AD biomarkers. Our study design also has several
limitations. First, although acquisition protocols were
harmonized across sites, they were not always identical
(e.g., use of HRRT vs PET-MR). For this reason, site will be
used as a covariate in all analyses. Some of the biomarkers
were only acquired at the Amsterdam site, which will re-
duce the statistical power for the analysis of these markers.
Conclusions
We collected a large European cognitively normal sam-
ple with an extensive panel of AD biomarkers available
Fig. 3 Amyloid abnormality on PET scan per age group (n = 58, 22%). Abnormal PET scan visually read on summed static PET images: 12% of
subjects aged 60–70 years, 16% of subjects between 70 and 80 years, and 36% of subjects 80 years and older had abnormal PET scan
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at baseline, with clinical follow-up planned after 2 years,
to identify healthy elderly individuals at risk for amyloid
pathology and future cognitive decline. Results from this
study will improve understanding of the pathophysiology
of AD and thereby help to adapt the design of secondary
prevention trials.
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